An interventional study of Intensive multifactorial therapy and Standard therapy in Type 2 Diabetes Mellitus and Diabetic Nephropathy, sponsored by Okayama University. Completed at 1 site in Japan. Open to participants aged 20 Years to 75 Years. Per ClinicalTrials.gov, last updated 2019-07-23.
Sponsored by Okayama University · Not applicable, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 394 studies in Diabetes Mellitus, Type 2 with a site in Japan — 23 open to participants now, 31 under way, 22 of them phase 3. Diabetes Mellitus, Type 2 · Japan.
Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, this one is the 154th largest by enrollment of the 334 interventional ones that give a count, is one of 3 that started in 2005, is one of 17 with no phase, and was the 12th registered.
10,403 studies on the registry are indexed under Diabetes Mellitus, Type 2; 1,413 are open to participants now.
Browse Diabetes Mellitus, Type 2 studies →23 of the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan are open now. Recruiting first, the newest first:
Eli Lilly and Company · Sites in Japan, United States, Argentina and 8 more countries
Ages 18+
Eli Lilly and Company · Sites in Japan, United States, Argentina and 1 more country
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 8 more countries
Ages 18+
AstraZeneca · Sites in Japan, United States, Argentina and 13 more countries
Ages 18+
Amgen · Sites in Japan, United States, Canada and 2 more countries
Ages 18–99
A study can be open while its sites in Japan have not opened yet or have stopped. Only those recruiting at a site in Japan →
Of the 882 Diabetes Mellitus, Type 2 studies recruiting now, 372 (42%) set no upper age limit and 384 (44%) stop at 75 or younger; 52 take children under 18; 202 take healthy volunteers.
This study: 20 Years to 75 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
394 studies; the count open now beside each. This study's row is marked.
A study in two phases is counted once above. Listed by phase, each with its combined phases: Phase 1 37 · Phase 2 52 · Phase 3 194 · Phase 4 50
First in 1999; this study’s year is marked. 3 started in 2005.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 312 is above the median of 80 across 8,372 interventional studies indexed under Diabetes Mellitus, Type 2.
Median enrollment 284 across the 334 interventional studies, 1,869 across the 51 observational. Of the 342 that completed or were terminated, 182 (53%) have results posted.
This tab as a report to print or save as PDF → With an account.
350 of 394 have an industry lead sponsor. The 10 most frequent:
Okayama University is the lead sponsor of 18 studies on the registry; 2 are open to participants now.
Okayama University has 1 study filed under Diabetes Mellitus, Type 2 — fewer than ten, so there is no comparison to draw.
8 of the studies in Diabetes Mellitus, Type 2 with a site in Japan that are under way reach primary completion within a year, 4 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06858878Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants With Type 2 Diabetes Mellitus Who Have Obesity or Are Overweight | 2027-01-21 |
| NCT06987695Phase 3AmgenEfficacy and Safety of Maridebart Cafraglutide in Adult Participants in Japan Who Have Obesity Disease | 2027-04-27 |
| NCT06993792Phase 3Eli Lilly and CompanyA Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes | 2027-08 |
| NCT06972472Phase 3Eli Lilly and CompanyA Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and Type 2 Diabetes | 2027-08 |
| NCT06151964AstraZenecaA Trial to Learn How Safe AZD9550 Monotherapy and Combined With AZD6234 is in People With or Without Type 2 Diabetes Who Are Living With Obesity and Overweight | 2027-01-29 |
Add all 8 to your calendar (.ics) → With an account.
Among the 394 studies in Diabetes Mellitus, Type 2 with a site in Japan, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Study for the effectiveness of intensive therapy aiming at the remission of diabetic nephropathy
Study for the effectiveness of intensive therapy for diabetic nephropathy in unblinded, randomized intergroup comparison study.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.
Other: Intensive multifactorial therapy
Protocol A: serum creatinine \<1.2 mg/dl in male and \<1.0 mg/dl in female.
Other: Standard therapy
Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
Other: Intensive multifactorial therapy
Protocol B: serum creatinine: 1.2-2.5 mg/dl in male and 1.0-2.5 mg/dl in female.
Other: Standard therapy
Blood glucose control: HbA1c \< 6.2% Blood pressure control: SBP \< 125 mmHg, DBP: \< 75 mmHg Lipid profile: T-cho \< 180 mg/dl, LDL-cho \< 100 mg/dl, HDL-cho \>40 mg/dl Dietary intervention: TDEI \< 30 kcal/kg/day, sodium \< 5 g/day, protein \< 0.8 g/kg/day Pharmacological intervention: ACE-Is or ARBs, HMG-CoA reductase inhibitors, multivitamins Instruction by co-medicals: Taking medicines, smoking cessation, nutrition care
Blood glucose control: HbA1c \< 6.9% Blood pressure control: SBP \< 130 mmHg, DBP: \< 80 mmHg Lipid profile: T-cho \< 200 mg/dl, LDL-cho \< 120 mg/dl, HDL-cho \>40 mg/dl, Dietary intervention: TDEI \< 25-30 kcal/kg/day, sodium \< 6 g/day, protein \< 1.0 g/kg/day Pharmacological intervention: No restrictions (continuing prior therapy) Instruction by co-medicals: No restrictions (continuing prior therapy)
Urinary protein/creatinine ratio (in the first morning urine sample) in Protocol A
Time frame: 5 years
Composite endpoint of time to first occurrence of (1) Doubling of serum creatinine, (2) Need for chronic dialysis or renal transplantation, or (3) Death in Protocol B
Time frame: 5 years
GFR in Protocol A
Time frame: 5 years
Cardiovascular event in Protocol A
Time frame: 5 years
Progression of retinopathy in Protocol A
Time frame: 5 years
Urinary albumin/creatinine ratio in Protocol A
Time frame: 5 years
Proteinuria (24 h collection sample) in Protocol A
Time frame: 5 years
GFR in Protocol B
Time frame: 5 years
Cardiovascular event in Protocol B
Time frame: 5 years
Progression of retinopathy in Protocol B
Time frame: 5 years
Urinary albumin/creatinine ratio in Protocol B
Time frame: 5 years
Urinary protein/creatinine ratio in Protocol B
Time frame: 5 years
Ran from Nov 2005 to primary completion in Nov 2014, 108 months.
Of 2,078 non-industry interventional studies with no phase under Diabetes Mellitus, Type 2, half reached primary completion within 21 months of starting (the median), counting those still running; a quarter within 10 and three quarters within 40. This study's 108 months is above that.
Counting every sponsor, half of 2,255 studies reached it within 21 months; a quarter within 10 and three quarters within 39.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Jul 2019. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Okayama University